FDA Peptide Tracker

BPC-157: live FDA regulatory status

Recovery peptide · RFK-14

The two signals

Plain-English verdict: amber.

Regulatory status: PCAC recommended · rulemaking pending.

These two never collapse into one. Removal from a list is not the same as legal-to-compound, and neither is the same as available.

Availability at Peptós.LIFE

Join waitlist

What BPC-157 is

A recovery peptide people take in hope of speeding the healing of tendon, joint, muscle, and gut lining.

Short version: the recovery peptide everyone's talking about, with loud buzz and thin human proof. It's under FDA review, so today it's a waitlist, not something you can legitimately get.

BPC-157 is the peptide the recovery world can't stop talking about. The interest is real; the evidence is early. We track its status honestly rather than pretend it's for sale.

Why it sits in this category

BPC-157 is tracked under RFK-14. Its regulatory status is PCAC recommended · rulemaking pending — a separate signal from whether you can actually get it today. We never collapse the two.

Not available to prescribe today. Removed from FDA Category 2, but that isn't 'legal to compound,' and it isn't 'available.' It goes before the PCAC on Jul 23–24, 2026; realistic earliest access is late 2026 into 2027.

A 15-amino-acid sequence derived from a protein in gastric juice; proposed to support angiogenesis and tissue repair signaling.

What it does — and what it does not do

What it does: Studied for soft-tissue and gut-lining repair support.

What it does not do: It is not a proven cure for any injury, and it is not approved or available to prescribe today.

What would have to change

Next milestone on the regulatory path: FDA rulemaking decision — Projected 2027. A favorable advisory (PCAC) vote is a recommendation that leads to rulemaking — not FDA approval, not authorization to compound, and not availability.

Evidence grade

Grade D — animal-dominant, fewer than 30 humans, no placebo-controlled efficacy trials. See our grading methodology for what each grade means.

What we still don't know: Fewer than 30 humans have been studied, with no placebo-controlled efficacy trials. Long-term safety is uncharacterized.

Regulatory timeline

PCAC is advisory: its Jul 2026 recommendation leads to rulemaking, not instant availability. A favorable advisory vote is a recommendation, not FDA approval or authorization to compound. Realistic earliest legitimate access is late 2026 into 2027. Reclassification is not the same as FDA approval. Compounded medications are not evaluated or approved by the FDA for safety, efficacy, or quality, where that applies, we say so, plainly.

Primary source: FDA source record

See the full status board or this molecule's knowledge-base monograph.

Last updated July 26, 2026 · Peptós.LIFE · Not medical advice.